This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

This study has been completed.
Information provided by (Responsible Party):
Santen Oy Identifier:
First received: February 28, 2011
Last updated: June 7, 2012
Last verified: June 2012

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.

This study will enroll patients who have ocular hypertension or glaucoma.

The study schedule includes seven visits to the study site and three stages:

  • washout of 5 days to 4 weeks depending on current glaucoma medication (if any)
  • 6-month study treatment period
  • 1-3 weeks post-study period

Condition Intervention Phase
Ocular Hypertension Open-angle Glaucoma Drug: Timolol and Tafluprost Drug: Fixed Dose Combination of tafluprost and timolol Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those of Tafluprost and Timolol Eye Drops Given Concomitantly in Patients With Open Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Further study details as provided by Santen Oy:

Primary Outcome Measures:
  • Change from baseline in the average diurnal intra-ocular pressure (IOP) at 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Change from baseline in average diurnal IOP at 2 weeks, 6 weeks and 3 months [ Time Frame: 2 weeks, 6 weeks and 3 months ]
  • Change from baseline in timewise IOPs [ Time Frame: 2 weeks, 6 weeks, 3 months and 6 months ]
    Change from baseline in timewise IOPs (at 8:00, 10:00, 16:00) at 2 weeks, 6 weeks, 3 months and 6 months

Enrollment: 401
Study Start Date: March 2011
Study Completion Date: May 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Timolol and Tafluprost
Concomitant administration of preservative-free timolol and tafluprost eye drops
Drug: Timolol and Tafluprost

Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily

Treatment period 6 months

Experimental: Fixed Dose Combination of tafluprost and timolol
Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
Drug: Fixed Dose Combination of tafluprost and timolol

Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.

For masking purposes also: vehicle for timolol administered twice daily

Treatment period 6 months


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18 years or more
  • A diagnosis of ocular hypertension or open-angle glaucoma
  • Meet specific IOP level at visit 1 (screening)and visit 2 (baseline)
  • Meet specific visual acuity score
  • Are willing to follow instructions
  • Have provided a written informed consent

Exclusion Criteria:

  • Females who are pregnant, nursing or planning pregnancy
  • IOP greater than 36 mmHg at any time point at screening or baseline
  • Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye
  • Suspected contraindication or hypersensitivity to study medications tafluprost or timolol (e.g. asthma, low pulse) or to wash-out medication brinzolamide
  • Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening
  • Use of contact lenses at Screening or during the study
  • Presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters
  • Current participation in another clinical trial within the last 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01306461

Debrecen, Hungary
Sponsors and Collaborators
Santen Oy
Study Director: Auli Ropo, M.D. Santen Oy
Principal Investigator: Clemens Vass, M.D. Medical University Vienna, Austria
Principal Investigator: Marieta Kostianeva, M.D. University Mulitiprofile Hospital for Active Treatment Sv.Georgi, Bulgaria
Principal Investigator: Eva Ruzickova, M.D. Vseobecna fakultni nemocnice v Praze, Czech Republic
Principal Investigator: Gábor Holló Semmelweis Egyetem, Hungary
Principal Investigator: Guna Laganovska, M.D. P. Stradina Clinical University Hospital, Latvia
Principal Investigator: Maria L. Ribeiro, M.D. Aibili-Associação p/ Investigação Biomédica e Inovação em Luz e Imagem (AIBILI), Portugal
Principal Investigator: Julián García-Feijóo, M.D. Hospital Clinico San Carlos, Spain
  More Information

Responsible Party: Santen Oy Identifier: NCT01306461     History of Changes
Other Study ID Numbers: 201051
Study First Received: February 28, 2011
Last Updated: June 7, 2012

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents
Antihypertensive Agents processed this record on September 21, 2017